Eli Lilly Shares Surge 3.9% as Analysts Remain Bullish

Pharmaceutical giant Eli Lilly sees stock price jump amid positive analyst sentiment

Apr. 1, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

Shares of pharmaceutical company Eli Lilly and Company (NYSE:LLY) rose 3.9% on Wednesday, trading as high as $976.68 per share. The stock surge comes as analysts maintain a largely positive outlook on the company, with the majority rating the stock as a 'Buy'.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of drugs across various therapeutic areas. The company's stock performance is closely watched by investors as an indicator of the broader pharmaceutical industry's health and investor sentiment.

The details

Eli Lilly's stock price jumped on Wednesday, with 6.17 million shares traded, a 91% increase from the average daily volume. The company's shares closed at $955.45, up 3.9% from the previous day's close of $919.77. Analysts have maintained a largely positive outlook on Eli Lilly, with 23 'Buy' ratings, 4 'Hold' ratings, and 1 'Sell' rating. The average price target for the stock is $1,221.26.

  • Eli Lilly's stock price surge occurred on Wednesday, April 1, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

What they’re saying

“Eli Lilly and Company has been the topic of several research analyst reports. Sanford C. Bernstein restated an 'outperform' rating on shares of the company.”

— Sanford C. Bernstein, Analyst

“Weiss Ratings reiterated a 'buy (b)' rating on shares of Eli Lilly and Company.”

— Weiss Ratings, Analyst

“Truist Financial reissued a 'buy' rating on shares of Eli Lilly and Company.”

— Truist Financial, Analyst

What’s next

Investors will be closely watching Eli Lilly's upcoming earnings report and any further updates from analysts on the company's performance and outlook.

The takeaway

Eli Lilly's strong stock performance and positive analyst sentiment reflect the company's position as a leading player in the pharmaceutical industry. The surge in trading volume suggests increased investor interest in the stock, which could signal further upside potential if the company continues to deliver on its growth initiatives.